<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/772A1E12-7175-46C0-B665-CE27930D15A8"><gtr:id>772A1E12-7175-46C0-B665-CE27930D15A8</gtr:id><gtr:name>Liverpool John Moores University</gtr:name><gtr:address><gtr:line1>Egerton Court</gtr:line1><gtr:line2>No 2 Rodney Street</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L3 5UX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/055E428B-EF35-46E3-83A6-4D4004294C32"><gtr:id>055E428B-EF35-46E3-83A6-4D4004294C32</gtr:id><gtr:name>University of Utah</gtr:name><gtr:address><gtr:line1>201 South Presidents Circle</gtr:line1><gtr:line2>Salt Lake City</gtr:line2><gtr:line4>Utah</gtr:line4><gtr:postCode>UT 84112</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/407A401F-2A36-44B0-AC22-C52E5A03CB27"><gtr:id>407A401F-2A36-44B0-AC22-C52E5A03CB27</gtr:id><gtr:name>Fresenius Kabi Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD"><gtr:id>9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD</gtr:id><gtr:name>Intensive Care Society</gtr:name><gtr:address><gtr:line1>Churcill House</gtr:line1><gtr:line2>38 Red Lion Square</gtr:line2><gtr:postCode>WC1R 4PN</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Clinical Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/772A1E12-7175-46C0-B665-CE27930D15A8"><gtr:id>772A1E12-7175-46C0-B665-CE27930D15A8</gtr:id><gtr:name>Liverpool John Moores University</gtr:name><gtr:address><gtr:line1>Egerton Court</gtr:line1><gtr:line2>No 2 Rodney Street</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L3 5UX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055E428B-EF35-46E3-83A6-4D4004294C32"><gtr:id>055E428B-EF35-46E3-83A6-4D4004294C32</gtr:id><gtr:name>University of Utah</gtr:name><gtr:address><gtr:line1>201 South Presidents Circle</gtr:line1><gtr:line2>Salt Lake City</gtr:line2><gtr:line4>Utah</gtr:line4><gtr:postCode>UT 84112</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/407A401F-2A36-44B0-AC22-C52E5A03CB27"><gtr:id>407A401F-2A36-44B0-AC22-C52E5A03CB27</gtr:id><gtr:name>Fresenius Kabi Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD"><gtr:id>9154D7A2-6DDE-43CF-AE50-0BA86A7BD2AD</gtr:id><gtr:name>Intensive Care Society</gtr:name><gtr:address><gtr:line1>Churcill House</gtr:line1><gtr:line2>38 Red Lion Square</gtr:line2><gtr:postCode>WC1R 4PN</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D73F1F06-FC58-4BFC-9D0F-D285BA9E92FB"><gtr:id>D73F1F06-FC58-4BFC-9D0F-D285BA9E92FB</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:surname>McArdle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/43B7E70C-EB52-4E0D-8BA9-47586DAB8C64"><gtr:id>43B7E70C-EB52-4E0D-8BA9-47586DAB8C64</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Griffiths</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400911"><gtr:id>3EC90290-DA7C-4ADF-9AB7-4DAF32B8E7D9</gtr:id><gtr:title>The role of heat shock proteins in glutamine-induced protection of skeletal muscle during sepsis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400911</gtr:grantReference><gtr:abstractText>The applicants are aware of the importance of public engagement in science. Dr McArdle was trained in media presentations as part of her Research into ageing-funded Fellowship and both applicants have participated in scientific interviews and discussions with local and national media and charity support groups.
Lay Summary:
Sepsis is the major cause of mortality in critically ill patients on the intensive care unit. Tissues of the critically ill patient in sepsis are exposed to a barrage of insults and this results in multiple organ failure. Despite detailed knowledge of multiple organ failure, treatment remains uncertain. Clinical experience suggests that the best hope for survival may be where circumstances allow the cells to withstand the attack and optimize their own defences. A patient with sepsis loses muscle at a staggering rate of 2-4 % per day. The ability to withstand sepsis appears to be particularly dependant upon available skeletal muscle. Over half of intensive care patients are over 65 years. The critical role of muscle mass in mortality during sepsis has profound implications for the elderly intensive care patient. The normal loss of skeletal muscle is such that a healthy individual aged 65 will have lost 30-40 %. The substantial rate of muscle loss during sepsis, taken together with this age-related loss is catastrophic and in the very least will prolong or inhibit subsequent recovery in the elderly and becomes a determinant of survival. We have identified a component of muscle, heat shock proteins (HSPs), which are crucial in maintaining muscle integrity in young and old individuals. The ability to produce HSPs fails in muscles of younger individuals during sepsis and the ability of muscles from even healthy elderly to produce HSPs in response to stresses is already severely compromised. A therapy which enhances the HSP content of muscle may provide significant benefit to both young and old individuals. Patients with sepsis have a marked deficiency of glutamine. Trials of patients fed glutamine during sepsis have shown that supplementation improves survival from multiple organ failure. However, the exact mechanism of glutamine action in these patients is unknown. Data from our laboratory and others suggests that glutamine may enhance HSP expression during stress and this is associated with protection of muscles. Understanding the role of HSPs in protecting against loss of muscle during sepsis and optimising the effects of glutamine is crucial to the development of a therapeutic rationale.</gtr:abstractText><gtr:technicalSummary>Cells and tissues of the critically ill in sepsis are exposed to an inflammatory process that has profound consequences resulting in multiple organ failure and significant mortality. Modulation of the inflammatory pathway is a therapeutic approach which has received considerable attention. However, results from this have been disappointing. Therapies that enhance endogenous protection, salvage and repair mechanisms offer an exciting new strategy. The rate of loss of muscle in septic intensive care patients with multiple organ failure is between 2 and 4% per day. The ability to withstand sepsis appears to be dependant upon available skeletal muscle. Half of severely ill intensive care patients are over 65 years. The normal age-related loss of skeletal muscle between the years of 20 to 80 produces a 40% loss of muscle bulk. This substantial rate of muscle loss, taken together with the age-related loss of up to 40% of muscle bulk is catastrophic. Muscle cells of young individually are able to respond to stress by a rapid increase in protective proteins. We have demonstrated that one important component of this adaptation, heat shock proteins (HSPs) is crucial in maintaining muscle integrity. The ability to produce HSPs fails in muscles of younger individuals during sepsis and the ability of muscles from healthy elderly to produce HSPs in response to stresses is already severely compromised. Trials of patients fed glutamine during sepsis have shown that supplementation improves survival from multiple organ failure. However, the exact mechanism of glutamine action in these patients is unknown. Data from our laboratory and others suggests that glutamine may enhance HSP expression during stress and this is associated with protection of muscles. The aim of this study is to use transgenic technology to provide a comprehensive picture of the role of HSPs in preservation of muscle function in young and old mice during sepsis. This will be accompanied by a physiological approach to examine the ability of glutamine supplementation to enhance HSP content and preserve muscle function. The mouse model of LPS dosing will be used. This model is well established and has been commonly used as a model for sepsis. The study will use a combination of histochemical analysis of structure and physiological measurements. Understanding the role of HSPs in protecting against loss of muscle during sepsis and optimising the effects of glutamine is crucial to the development of a therapeutic rationale.</gtr:technicalSummary><gtr:fund><gtr:end>2008-12-19</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-20</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>236948</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fresenius Kabi Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Translational collaboration with Fresenius Kabi company (Germany)</gtr:description><gtr:id>ACEF5188-30C1-453A-8AF7-31B72EABFBC4</gtr:id><gtr:impact>17713407 in addition to two submitted publications.</gtr:impact><gtr:partnerContribution>Provision of glutamine supplement material for patients in ITU.</gtr:partnerContribution><gtr:piContribution>Translation of animal work to the clinical setting as a pilot clinical trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of transgenic mice</gtr:description><gtr:id>86027DED-0239-4AF3-9AA1-82BF097FB102</gtr:id><gtr:impact>Publications prior to this study not included and publications directly resulting from this collaboration submitted.</gtr:impact><gtr:partnerContribution>Provision of a panel of transgenic mice appropriate to the study.</gtr:partnerContribution><gtr:piContribution>Analysis of muscle function and, where an effect seen, biochemical analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Utah</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of GM HSF1 null mice</gtr:description><gtr:id>1D0495CF-0575-4FCE-8C21-9DD525D9436F</gtr:id><gtr:impact>Publication in preparation.</gtr:impact><gtr:partnerContribution>Provision of HSF1 - null mice.</gtr:partnerContribution><gtr:piContribution>analysis of the effect of an inability to activate the heat shock transcription factor on sepsis-induced changes in muscle function and illness severity.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool John Moores University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Sport and Exercise Science</gtr:department><gtr:description>Human muscle functional studies</gtr:description><gtr:id>B322E040-4B92-4691-A39A-558ED44C624F</gtr:id><gtr:impact>17488245 and this has led to a number of other publications not directly related to sepsis.</gtr:impact><gtr:partnerContribution>The provision of functional testing staff and equipment to develop a means of examining the role of HSPs in modulating muscle function.</gtr:partnerContribution><gtr:piContribution>The expertise on HSP function in muscle and access to laboratories for analyses.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intensive Care Society</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Intensive Care Society</gtr:description><gtr:id>9601545C-1826-483C-90C9-0C0E219B5B88</gtr:id><gtr:impact>17713407 and two submitted publications.</gtr:impact><gtr:piContribution>The team provided the basis of a mechanistic study to understand the function of glutamine in improving outcome from intensive care, with both clinical and laboratory support for the pilot study.</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC news on-line</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5E89D03B-FA94-4EBD-BE6B-642C14C29B9C</gtr:id><gtr:impact>Asked to comment on news reports. Although not directly related to outputs form this research, relevant in general terms.

Some contact from other organisations to advise regarding glutamine supplementation in ITU (RDG) or general muscle function and ageing (AMcA)</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Engagement at World Museum Liverpool</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>23A730C7-2AA0-49DA-B86C-611D1A84EDCA</gtr:id><gtr:impact>A large set of activities aimed at engagement of children with science, with focus on funded research areas within the Department/Institute.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School placements</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>926DE57F-068B-458F-AC41-BD1451049FD8</gtr:id><gtr:impact>School sixth form work experience in laboratories.

Led to a better understanding of the support or lack of support provided to inner-city schoolchildren with no background in higher education in their family.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC DRINC</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>61D95814-EA26-425A-BF35-D54C84D6D3FF</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Dowager Countess Eleanor Peel Trust</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>The Dowager Countess Eleanor Peel Trust</gtr:fundingOrg><gtr:id>62213403-33AB-4347-9C5B-F50B6BB179B1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE guidelines (RDG)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>465977A3-C4EC-49B2-8075-F4150BEA599E</gtr:id><gtr:impact>Professor Griffiths has implemented NICE guidelines related to ITU and parenteral nutrition/glutamine.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Review on ageing research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B05E16F-8F75-43CB-B855-275612342FE3</gtr:id><gtr:impact>This review of ageing research in the UK highlighted loss of skeletal muscle mass and function as an underfunded area of research and led to RCs highlighting this as a priority area. Also led to the formation of the British Council on Ageing as a source of information for government policy makers and Professor McArdle sits on this Council.</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/255E2D37-62BC-465C-ADAC-BB4211260FB5"><gtr:id>255E2D37-62BC-465C-ADAC-BB4211260FB5</gtr:id><gtr:title>Editorial: Endurance Exercise: An Important Therapeutic Adjuvant in the Overall Treatment of Myositis?</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d87b2c25af8fb66c68418f96f618c7a"><gtr:id>4d87b2c25af8fb66c68418f96f618c7a</gtr:id><gtr:otherNames>Lightfoot AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E86D5876-5FB3-48FE-82A1-CCC2A1ACC219"><gtr:id>E86D5876-5FB3-48FE-82A1-CCC2A1ACC219</gtr:id><gtr:title>Overexpression of HSP10 in skeletal muscle of transgenic mice prevents the age-related fall in maximum tetanic force generation and muscle Cross-Sectional Area.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Regulatory, integrative and comparative physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55e1376ff8a44ac688926e7ea1b6ebb4"><gtr:id>55e1376ff8a44ac688926e7ea1b6ebb4</gtr:id><gtr:otherNames>Kayani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0363-6119</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18A17327-38A2-49AF-9A55-697CA7045BE0"><gtr:id>18A17327-38A2-49AF-9A55-697CA7045BE0</gtr:id><gtr:title>In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness?</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d87b2c25af8fb66c68418f96f618c7a"><gtr:id>4d87b2c25af8fb66c68418f96f618c7a</gtr:id><gtr:otherNames>Lightfoot AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8522E9CA-40C3-4E2D-A2F5-C93A70D745ED"><gtr:id>8522E9CA-40C3-4E2D-A2F5-C93A70D745ED</gtr:id><gtr:title>The role of hormones, cytokines and heat shock proteins during age-related muscle loss.</gtr:title><gtr:parentPublicationTitle>Clinical nutrition (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73dc47582c3291d0cdd79a9900cbdfba"><gtr:id>73dc47582c3291d0cdd79a9900cbdfba</gtr:id><gtr:otherNames>Lee CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0261-5614</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED6B43CF-10E5-4C92-B752-D802241CCCD4"><gtr:id>ED6B43CF-10E5-4C92-B752-D802241CCCD4</gtr:id><gtr:title>Glutamine and tight glycemic control: chicken or egg?</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fd6ddc59c86ed48152c514613d3fa860"><gtr:id>fd6ddc59c86ed48152c514613d3fa860</gtr:id><gtr:otherNames>Griffiths RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1231AFB0-17D4-4A4B-8926-531AD3EDF06A"><gtr:id>1231AFB0-17D4-4A4B-8926-531AD3EDF06A</gtr:id><gtr:title>Exogenous glutamine: the clinical evidence.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/67634710075029e75b7f4fa54ef9c854"><gtr:id>67634710075029e75b7f4fa54ef9c854</gtr:id><gtr:otherNames>Bongers T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4E265BEC-D61D-4FCB-8170-9063418097A0"><gtr:id>4E265BEC-D61D-4FCB-8170-9063418097A0</gtr:id><gtr:title>Elevated core and muscle temperature to levels comparable to exercise do not increase heat shock protein content of skeletal muscle of physically active men.</gtr:title><gtr:parentPublicationTitle>Acta physiologica (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db8568bad341b4a02547f7e2fdaeac1f"><gtr:id>db8568bad341b4a02547f7e2fdaeac1f</gtr:id><gtr:otherNames>Morton JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1748-1708</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A1AEBDEB-58A6-4E7A-9C5A-DB2AB343A80D"><gtr:id>A1AEBDEB-58A6-4E7A-9C5A-DB2AB343A80D</gtr:id><gtr:title>Muscle in defense.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eff5fe552b9d1d41f73735f206c14196"><gtr:id>eff5fe552b9d1d41f73735f206c14196</gtr:id><gtr:otherNames>Lightfoot A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400911</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>